Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - rivaroxaban, quantity: 15 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hypromellose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; iron oxide red; macrogol 3350; titanium dioxide - ixarola is indicated for: ? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks) ? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke ? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe, ixarola, in combination with aspirin, is indicated for ? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - rivaroxaban, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; croscarmellose sodium; hypromellose; lactose monohydrate; iron oxide red; titanium dioxide; macrogol 3350; magnesium stearate - ixarola is indicated for: ? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks) ? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke ? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe, ixarola, in combination with aspirin, is indicated for ? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - testosterone enantate, quantity: 250 mg/ml (equivalent: testosterone, qty 180 mg/ml) - injection - excipient ingredients: benzyl benzoate; castor oil - indications as at 15 feb 1996 : androgen replacement therapy for confirmed testosterone deficiency in males.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - testosterone undecanoate, quantity: 1000 mg - injection - excipient ingredients: benzyl benzoate; castor oil - testosterone replacement in primary and secondary male hypogonadism.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - testosterone undecanoate, quantity: 1000 mg - injection - excipient ingredients: benzyl benzoate; castor oil - testosterone replacement in primary and secondary male hypogonadism.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nifedipine, quantity: 30 mg - tablet, modified release - excipient ingredients: magnesium stearate; cellulose acetate; polyethylene oxide; macrogol 3350; hypromellose; iron oxide red; sodium chloride; titanium dioxide; propylene glycol; hyprolose; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - indications: nifedipine is indicated for: 1. the treatment of mild to moderate hypertension. 2. the prophylaxis of chronic stable angina pectoris.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nifedipine -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nifedipine -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept, quantity: 40 mg/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; sucrose; water for injections; polysorbate 20 - eylea (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet amd) - visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo) - diabetic macular oedema (dme) - visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo) - visual impairment due to myopic choroidal neovascularisation (myopic cnv)

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept, quantity: 40 mg/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sucrose; polysorbate 20; sodium chloride; water for injections; dibasic sodium phosphate heptahydrate - eylea (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet amd); - visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo); - diabetic macular oedema (dme); - visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo); - visual impairment due to myopic choroidal neovascularisation (myopic cnv)